Active, not recruitingPHASE1, PHASE2NCT02333760
Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome
Studying Wiskott-Aldrich syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Genethon
- Intervention
- Autologous CD34+ cells transduced with WASP lentiviral vector(genetic)
- Enrollment
- 10 enrolled
- Eligibility
- MALE
- Timeline
- 2014 – 2032
Study locations (2)
- Hopital Necker - Enfants Malades, Paris, France
- UCL Institute of Child Health, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02333760 on ClinicalTrials.govOther trials for Wiskott-Aldrich syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07534033Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung CancerZhujiang Hospital
- ACTIVE NOT RECRUITINGPHASE3NCT03837483A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich SyndromeFondazione Telethon